Literature DB >> 17827736

Change in pharmacokinetics of model compounds with different elimination processes in rats during hypothermia.

Koyo Nishida1, Madoka Okazaki, Ryuichi Sakamoto, Natsuko Inaoka, Hideaki Miyake, Shintaro Fumoto, Junzo Nakamura, Mikiro Nakashima, Hitoshi Sasaki, Mikio Kakumoto, Toshiyuki Sakaeda.   

Abstract

We compared the pharmacokinetics of model compounds with different elimination processes between hypothermic and normothermic rats, to obtain basic information concerning drug therapy during hypothermia. Male Wistar rats were anesthetized with sodium pentobarbital and kept at temperatures of 37 degrees C (normothermic group) by heat lamp, and 32 degrees C or 28 degrees C (hypothermic group) by external cooling. We chose phenolsulfonphthalein (PSP), indocyanine green (ICG) and fluorescein isothiocyanate (FITC)-dextran (FD-4, Mw 4400) as model compounds to determine changes in clearance pathways during hypothermia therapy. The plasma concentrations of PSP as biliary, urinary and metabolic elimination type were increased significantly in the hypothermic group (32 degrees C, 28 degrees C) after i.v. administration at a dose of 1 mg, compared to the normothermic group (37 degrees C). Each PSP clearance (bile, urine and metabolites) in the hypothermic group was decreased, suggesting an influence of hypothermia on the active elimination process. The decreasing tendency was marked at a temperature of 28 degrees C. Moreover, the plasma concentrations of ICG as the biliary excretion type after i.v. administration to the hypothermic rats at a dose of 1 mg were higher with more than 50% decrease in the total body clearance compared to normothermic rats. On the other hand, there was almost no difference in the i.v. pharmacokinetics of FD-4 as the urinary excretion type between 37 degrees C and 32 degrees C. However, renal clearance of FD-4 was significantly decreased at a temperature of 28 degrees C. Accordingly, the change in pharmacokinetics of a drug in the hypothermic group could differ with the elimination processes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17827736     DOI: 10.1248/bpb.30.1763

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  6 in total

1.  Mild hypothermia decreases fentanyl and midazolam steady-state clearance in a rat model of cardiac arrest.

Authors:  Philip E Empey; Tricia M Miller; Ashley H Philbrick; John A Melick; Patrick M Kochanek; Samuel M Poloyac
Journal:  Crit Care Med       Date:  2012-04       Impact factor: 7.598

Review 2.  Effects of hypothermia on pharmacokinetics and pharmacodynamics: a systematic review of preclinical and clinical studies.

Authors:  Marcel P H van den Broek; Floris Groenendaal; Antoine C G Egberts; Carin M A Rademaker
Journal:  Clin Pharmacokinet       Date:  2010-05       Impact factor: 6.447

Review 3.  The effect of therapeutic hypothermia on drug metabolism and response: cellular mechanisms to organ function.

Authors:  Jiangquan Zhou; Samuel M Poloyac
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-04-08       Impact factor: 4.481

Review 4.  Effect of Hypothermia and Targeted Temperature Management on Drug Disposition and Response Following Cardiac Arrest: A Comprehensive Review of Preclinical and Clinical Investigations.

Authors:  Kacey B Anderson; Samuel M Poloyac; Patrick M Kochanek; Philip E Empey
Journal:  Ther Hypothermia Temp Manag       Date:  2016-09-13       Impact factor: 1.286

5.  Moderate hypothermia prevents cardiac arrest-mediated suppression of drug metabolism and induction of interleukin-6 in rats.

Authors:  Michael A Tortorici; Ying Mu; Patrick M Kochanek; Wen Xie; Samuel M Poloyac
Journal:  Crit Care Med       Date:  2009-01       Impact factor: 7.598

6.  Small Intestinal Permeability and Gut-Transit Time Determined with Low and High Molecular Weight Fluorescein Isothiocyanate-Dextrans in C3H Mice.

Authors:  Anni Woting; Michael Blaut
Journal:  Nutrients       Date:  2018-05-28       Impact factor: 5.717

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.